US 12,144,833 B1
Copper chelation therapeutics
David Gordon Bermudes, Woodland Hills, CA (US)
Filed by David Gordon Bermudes, Woodland Hills, CA (US)
Filed on Oct. 17, 2022, as Appl. No. 17/967,886.
Application 17/967,886 is a division of application No. 16/812,237, filed on Mar. 6, 2020, granted, now 11,471,497, issued on Oct. 18, 2022.
Claims priority of provisional application 62/895,961, filed on Sep. 4, 2019.
Claims priority of provisional application 62/817,970, filed on Mar. 13, 2019.
Int. Cl. A61K 35/741 (2015.01); A61K 35/74 (2015.01); A61P 25/00 (2006.01); C12N 1/20 (2006.01)
CPC A61K 35/74 (2013.01) [A61P 25/00 (2018.01); C12N 1/20 (2013.01); C12N 2510/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a patient having an excess of one or more transition metals in a tissue, by reducing the amount of the transition metal(s) in the tissue, comprising:
(a) administering a non-pathogenic live bacterium to the patient, the non-pathogenic live bacterium being genetically engineered to express and secrete a heterologous transition metal binding protein which sequesters transition metals in an environment surrounding the non-pathogenic live bacterium;
(b) colonizing an enteric tissue of the patient with the non-pathogenic live bacterium; and
(c) effectively reducing the availability of the transition metal(s) from dietary sources to the patient by the secretion of the heterologous transition metal binding protein and subsequent sequestration of the transition metal(s), to thereby treat the excess of transition metal(s) in the patient.